| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$61 |
Board Update
|
9 Sep 2025 8:36AM |
$0.800 |
$0.400 |
fallen by
50%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$61 |
S&P DJI Announces September 2025 Quarterly Rebalance
|
5 Sep 2025 5:08PM |
$0.840 |
$0.400 |
fallen by
52.38%
|
|
TRJ - Price-sensitive ASX Announcement
Full Release
Key Points
- Trajan Group Holdings Limited (TRJ) removed from S&P/ASX All Technology Index.
- Rebalance effective prior to the open on September 22, 2025.
- Changes part of the regular quarterly review by S&P Dow Jones Indices.
- Announcement made by S&P Dow Jones Indices on September 5, 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$61 |
Change in substantial holding
|
2 Sep 2025 12:18PM |
$0.920 |
$0.400 |
fallen by
56.52%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$61 |
2025 Annual General Meeting
|
28 Aug 2025 8:16AM |
$0.930 |
$0.400 |
fallen by
56.99%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$61 |
FY25 Appendix 4G and Corporate Governance Statement
|
28 Aug 2025 8:16AM |
$0.930 |
$0.400 |
fallen by
56.99%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$61 |
FY25 Financial Results Presentation
|
28 Aug 2025 8:15AM |
$0.930 |
$0.400 |
fallen by
56.99%
|
|
TRJ - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased across all segments.
- nEBITDA improved despite transient costs.
- Net Debt to nEBITDA ratio improved to 1.9 times.
- Global sales growth in North America, EMEA, and Asia-Pacific.
- Launch of innovative products like HDX Pro software.
- Establishment of comprehensive emissions baselines for ESG progress.
- Management expects FY26 net revenue between $170M to $180M and nEBITDA between $16M to $19M.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$61 |
FY25 Financial Results Presentation
|
28 Aug 2025 8:15AM |
$0.930 |
$0.400 |
fallen by
56.99%
|
|
TRJ - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased by 7.4% to $166.5 million.
- nEBITDA rose by 26.2% to $15.5 million.
- Net debt to nEBITDA ratio improved to 1.9 times.
- Focus on product development, including a dilution and filtration module and 21 CFR Part 11 compliant CDS.
- Continued growth trajectory in North America, EMEA, and Asia-Pacific.
- Precision manufacturer and preferred partner for global OEMs.
- Operating in Components & Consumables, Capital Equipment, and Disruptive Technologies segments.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$61 |
FY25 Financial Results Release
|
28 Aug 2025 8:14AM |
$0.930 |
$0.400 |
fallen by
56.99%
|
|
TRJ - Price-sensitive ASX Announcement
Full Release
Key Points
- Record revenue of $166.5M, a 7.4% growth over the previous year.
- Strong performance in Components and Consumables segment with $102.7M revenue.
- Cash and equivalents increased to $11.9M, with a focus on cash generation.
- Net debt reduced to $29.5M, improving the Net Debt/nEBITDA ratio.
- Gross margin was 39.8%, and normalized EBITDA was $15.5M.
- Outlook for FY26: Net Revenue of $170M to $180M and nEBITDA of $16M to $19M.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$61 |
FY25 Financial Results Release
|
28 Aug 2025 8:14AM |
$0.930 |
$0.400 |
fallen by
56.99%
|
|
TRJ - Price-sensitive ASX Announcement
Full Release
Key Points
- Record revenue of $166.5M in FY25, a 7.4% increase.
- Revenue exceeded guidance range.
- Growth driven by Components and Consumables, Capital Equipment, and Disruptive Technologies.
- Gross margins decreased to 39.8%.
- nEBITDA improved to $15.5M.
- Significant debt reduction and cash position strengthening.
- Long-term debt structure optimization.
- Focus on globalization of food safety testing and consumables growth.
- FY26 guidance: revenue between $170M to $180M, nEBITDA $16M to $19M.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$61 |
FY25 Appendix 4E and Annual Report
|
28 Aug 2025 8:14AM |
$0.930 |
$0.400 |
fallen by
56.99%
|
|
TRJ - Price-sensitive ASX Announcement
Full Release
Key Points
- FY25 revenue was $166.5 million, primarily from goods sales.
- Loss after tax was $4.46 million.
- Total assets amounted to $195.6 million with liabilities at $90.0 million.
- Net assets stood at $105.6 million.
- Depreciation and amortization were key expenses.
- Share-based payments and options details included.
- Commitment to corporate governance stated.
- Auditor's independence declaration included.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$61 |
FY25 Appendix 4E and Annual Report
|
28 Aug 2025 8:14AM |
$0.930 |
$0.400 |
fallen by
56.99%
|
|
TRJ - Price-sensitive ASX Announcement
Full Release
Key Points
- Trajan Group Holdings Limited reported a 7.4% increase in revenue to $166.5 million for the year ended 30 June 2025.
- The company recorded a loss after tax of $4.46 million, a significant reduction from the previous year's loss of $25.33 million.
- No dividends were declared for the year ended 30 June 2025.
- The company did not acquire any entities during the financial year.
- Capital commitments were reported at $411,000 for the upcoming year.
- No significant events were reported post the financial year-end that would affect future operations.
- Trajan Group Holdings Limited and its subsidiaries have been audited and received an unqualified opinion.
- Key management personnel changes included the cessation of roles for Dr. Andrew Gooley and Nigel Gilligan from 1 July 2024.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$61 |
TRJ FY25 Full Year Results and Investor Webcast Notification
|
7 Aug 2025 3:47PM |
$0.950 |
$0.400 |
fallen by
57.89%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$61 |
Market Update - Trajan set to report strong top line growth
|
5 Aug 2025 9:08AM |
$0.810 |
$0.400 |
fallen by
50.62%
|
|
TRJ - Price-sensitive ASX Announcement
Full Release
Key Points
- Trajan expects FY23 revenue of $148 million to $151 million, reflecting 24% to 27% growth over FY22.
- Revenue growth is attributed to strong organic performance and recent acquisitions, including Neoteryx.
- The company focuses on expanding its product range, geographic presence, and customer base.
- Growth is particularly strong in the life sciences and analytical laboratory sectors.
- Full year results with detailed financial metrics and commentary will be released in August 2023.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$61 |
Notification of cessation of securities - TRJ
|
27 Jun 2025 4:30PM |
$0.730 |
$0.400 |
fallen by
45.21%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$61 |
Trajan Operational Update
|
29 May 2025 9:12AM |
$0.830 |
$0.400 |
fallen by
51.81%
|
|
TRJ - Price-sensitive ASX Announcement
Full Release
Key Points
- Reported strong revenue growth and improved gross margins for the half-year ended 31 December 2023.
- Successful integration of acquired businesses contributed positively to overall performance.
- Portfolio expansion in laboratory automation and workflow seen as a major driver of future growth.
- Sustained demand in analytical consumables supports robust commercial activity.
- Ongoing investments in operational efficiencies and new product development.
- Emphasis on expanding global market presence and customer base.
- Company reaffirms FY24 guidance and outlook for continued revenue and margin growth.
- Commitment to innovation and strategic execution to deliver long-term shareholder value.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$61 |
Change of Director's Interest Notice
|
8 Apr 2025 10:23AM |
$0.740 |
$0.400 |
fallen by
45.95%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$61 |
Application for quotation of securities - TRJ
|
8 Apr 2025 10:21AM |
$0.740 |
$0.400 |
fallen by
45.95%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$61 |
Change in substantial holding
|
13 Mar 2025 4:23PM |
$0.900 |
$0.400 |
fallen by
55.56%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$61 |
H1 FY25 Financial Results Presentation
|
27 Feb 2025 8:09AM |
$0.830 |
$0.400 |
fallen by
51.81%
|
|
TRJ - Price-sensitive ASX Announcement
Full Release
Key Points
- Record revenue achieved in H1 FY25 of $81.0 million.
- nEBITDA increased to $7.9 million from $4.0 million in the previous year.
- Components & Consumables revenue grew by 15-20% over the previous corresponding period.
- Capital Equipment order book increased by $2.4 million.
- Investment in disruptive technologies continues with planned commercial launches.
- Financial guidance for FY25 maintained with a focus on margin improvement.
- Strong customer demand momentum and order book supporting growth.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$61 |
H1 FY25 Financial Results Release
|
27 Feb 2025 8:09AM |
$0.830 |
$0.400 |
fallen by
51.81%
|
|
TRJ - Price-sensitive ASX Announcement
Full Release
Key Points
- Group Net Revenue $81.0M, up 6.0% on previous corresponding period.
- Components & Consumables segment $48.9M, up 4.9%.
- Capital Equipment segment $29.9M, up 8.1%.
- Group Normalised EBITDA $7.9M, up 97.2%.
- Operating NPATA of $1.0M.
- Net Debt decreased by $2.3M to $30.6M.
- Guidance maintained for FY25 Net Revenue of $160.0M to $165.0M.
- Customer demand showed strong growth compared to H1FY24.
- Investment in Disruptive Technologies expected to be around $1.0M.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$61 |
H1 FY25 Appendix 4D and Interim Report
|
27 Feb 2025 8:08AM |
$0.830 |
$0.400 |
fallen by
51.81%
|
|
TRJ - Price-sensitive ASX Announcement
Full Release
Key Points
- Trajan Group's revenue for H1 FY25 was $81.0 million, a 6% increase from H1 FY24.
- The company reported a net loss of $3.5 million for the period.
- Strong organic growth was observed in the Components and Consumables segment.
- Trajan emphasizes the importance of reliable analytical data for human health.
- The company has invested significantly in its manufacturing capabilities in Malaysia.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$61 |
FY25 Half Year Results and Investor Webcast Notification
|
3 Feb 2025 9:32AM |
$0.920 |
$0.400 |
fallen by
56.52%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$61 |
Application for quotation of securities - TRJ
|
2 Jan 2025 4:10PM |
$1.000 |
$0.400 |
fallen by
60%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$61 |
Change of Director's Interest Notice
|
24 Dec 2024 8:21AM |
$1.020 |
$0.400 |
fallen by
60.78%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$61 |
Change of Director's Interest Notice
|
25 Nov 2024 12:42PM |
$0.905 |
$0.400 |
fallen by
55.80%
|
|
Call 1300 880 160
Start a chat
Schedule a call
